Table 1 . Clinical and treatment details of patients who developed SJS or TEN following COVID-19 vaccination .
a Organ failure; 92/M with renal insufficiency (creatinine clearance levels: 46.94 mL/min, and azotaemia: 1.10 g/L), electrolyte disorders (hypernatremia: 150 mmol/L), thrombocytopenia (77,000/mm3)
bNon-survivor
c Respiratory failure BSA: body surface area; CARSs: cutaneous adverse reactions; ChAdOx1 nCov-19 vaccination: adenoviral vector-based vaccine; D: day of illness; DM: diabetes mellitus; DVT: deep venous thrombosis; ICU: intensive care unit; IVIG: intravenous immunoglobulin; mRNA: messenger ribonucleic acid; OHA: oral hypoglycaemic drugs; SARS-CoV-2: severe acute respiratory syndrome related corona virus; SCARs: severe cutaneous adverse reactions; TEN: toxic epidermal necrolysis; SJS: Steven Johnson syndrome.
|
NO |
Age /Sex |
Comorbidities |
Type of vaccine and dose |
SCARs |
Clinical presentation and [day of onset after vaccination] |
Treatment |
Day of healing of skin lesion |
Author/Reference |
|
1 |
49/F |
No |
mRNA,1 st |
TEN |
Fever, Skin eruptions [D7] |
Etanercept |
D-22 |
Bakir et al. 7 |
|
2 |
Middle age /F |
No |
mRNA,2 nd |
SJS |
Fever, Red coloured bullae [D5] |
Oral steroid |
Not mentioned |
Elboraey and Essa. 13 |
|
3 |
12/F |
No |
mRNA,1 st |
TEN |
Fever, erythematous patches [D6] |
IVIG |
D-12 |
Siripipattanamongkol et al. 3 |
|
4 |
46/F |
Type 2 DM Hyperlipidaemia, Obesity |
mRNA,1 st |
SJS |
Oral discomfort, mucosal sloughing [D2] |
Oral steroid |
D-6 |
Padniewski et al. 2 |
|
5 |
86/F |
Tinea Pedis on oral Terbinafine |
mRNA, 3rd |
TEN |
Painful pruritic rash on left arm [D1] |
IV steroid |
D-20 |
Han et al. 4 |
|
6 |
32/M |
No |
Inactivated virus vaccine,2 nd |
SJS |
Blistering rash, erythematous plaque and punctate keratitis [D1] |
Ocular steroid |
D-10 |
Boualila et al. 11 |
|
7 |
92/M a , b |
Hypertension |
Inactivated virus vaccine,1 st |
TEN |
Painful skin lesions-necrosis [D20] |
Supportive |
Not mentioned |
Seck et al. 6 |
|
8 |
76/M |
No |
Inactivated virus vaccine,1 st |
TEN |
Skin lesions-blisters [D1] |
Oral steroid |
D-14 |
Mardani et al. 5 |
|
9 |
49/F |
Carcinoma breast |
Inactivated virus vaccine,2 nd |
SJS |
Ulcer in oral cavity and vagina [D3] |
Oral steroid |
D-14 |
Mansouri et al. 8 |
|
10 |
63/F |
Diabetes mellitus on OHA, Mild plaque type psoriasis |
Inactivated virus vaccine,1 st |
SJS |
Bullous rash and lip ulcers [D1] |
Oral steroids |
D-7 |
Mansouri et al. 12 |
|
11 |
48/F |
No |
ChAdOx1nCoV-19,1 st |
TEN |
Erythematous eruption [D14] |
Monoclonal antibody |
D-28 |
Kherlopian at al. 9 |
|
13 |
65/M |
No |
ChAdOx1nCoV-19,2 nd |
SJS |
Mucocutaneous eruptions, DVT, Sagittal sinus thrombosis [D10] |
Oral corticosteroid |
Not mentioned |
Aimo et al. 10 |
|
14 |
58/M c |
Type 2 DM |
ChAdOx1nCoV-19,3 rd |
TEN |
Pruritic lesion-blisters and necrosis [D10] |
IVIG |
D-30 |
Our case |